All patients
corticosteroids: no corticosteroids: yes critical disease severe disease
anti-interleukin-6 in COVID-19 severe or critically - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results COVACTA (Rosas), 2020 1.02 [0.62; 1.68]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
0.97 [0.72 ; 1.32 ] COVACTA (Rosas), 2020, Rosas (REMDACTA), 2021 2 0% 1,078 moderate not evaluable deathsdetailed results COVACTA (Rosas), 2020 1.16 [0.73; 1.84]
Lescure (Sarilumab 200mg), 2021 1.23 [0.49; 3.12]
Lescure (Sarilumab 400mg), 2021 0.97 [0.38; 2.50]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
1.04 [0.80 ; 1.36 ] COVACTA (Rosas), 2020, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Rosas (REMDACTA), 2021 4 0% 1,592 moderate not evaluable deaths (time to event analysis only)detailed results COVACTA (Rosas), 2020 1.16 [0.73; 1.84]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
1.03 [0.77 ; 1.38 ] COVACTA (Rosas), 2020, Rosas (REMDACTA), 2021 2 0% 1,092 moderate not evaluable clinical improvementdetailed results COVACTA (Rosas), 2020 1.19 [0.81; 1.75]
Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41]
1.09 [0.85 ; 1.39 ] COVACTA (Rosas), 2020, Lescure (Sarilumab 200mg), 2021 2 0% 685 moderate not evaluable clinical improvement (28-day)detailed results COVACTA (Rosas), 2020 1.19 [0.81; 1.75]
1.19 [0.81 ; 1.75 ] COVACTA (Rosas), 2020 1 0% 438 NA not evaluable clinical improvement (time to event analysis only)detailed results Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41]
Lescure (Sarilumab 400mg), 2021 1.14 [0.84; 1.54]
1.09 [0.87 ; 1.35 ] Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021 2 0% 506 moderate not evaluable death or ventilationdetailed results Rosas (REMDACTA), 2021 0.98 [0.72; 1.34]
0.98 [0.72 ; 1.34 ] Rosas (REMDACTA), 2021 1 0% 649 NA not evaluable hospital dischargedetailed results Rosas (REMDACTA), 2021 0.97 [0.79; 1.20]
0.97 [0.79 ; 1.20 ] Rosas (REMDACTA), 2021 1 0% 649 NA not evaluable mechanical ventilationdetailed results COVACTA (Rosas), 2020 0.67 [0.39; 1.14]
0.67 [0.39 ; 1.14 ] COVACTA (Rosas), 2020 1 0% 273 NA not evaluable ICU admissiondetailed results COVACTA (Rosas), 2020 0.48 [0.25; 0.94]
0.48 [0.25 ; 0.94 ] COVACTA (Rosas), 2020 1 0% 191 NA not evaluable serious adverse eventsdetailed results COVACTA (Rosas), 2020 0.81 [0.54; 1.22]
Lescure (Sarilumab 200mg), 2021 1.15 [0.62; 2.12]
Lescure (Sarilumab 400mg), 2021 1.38 [0.76; 2.51]
Rosas (REMDACTA), 2021 0.83 [0.59; 1.18]
0.93 [0.74 ; 1.16 ] COVACTA (Rosas), 2020, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Rosas (REMDACTA), 2021 4 0% 1,582 moderate not evaluable adverse eventsdetailed results COVACTA (Rosas), 2020 0.87 [0.52; 1.45]
Lescure (Sarilumab 200mg), 2021 0.97 [0.56; 1.69]
Lescure (Sarilumab 400mg), 2021 1.31 [0.76; 2.27]
Rosas (REMDACTA), 2021 1.32 [0.92; 1.89]
1.14 [0.90 ; 1.45 ] COVACTA (Rosas), 2020, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Rosas (REMDACTA), 2021 4 0% 1,582 moderate not evaluable 0.2 2.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-02 13:14 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 91
- treatments: 557,635,1236,553,628,646,645,607,395
- roots T: 290
